Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01
Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
Salvatore Siena, MD, a professor in the Department of Oncology and Hemato-Oncology at Universita degli Studi di Milano, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC) who have progressed on 2 or more treatments in this setting.
Siena believes that the results of this open-label, multicenter study were quite remarkable because the confirmed overall response rate was 45.3% in cohort A, which included 53 patients with mCRC and HER2 immunohistochemistry (IHC) of 3+, or IHC of 2+ and ISH positive. There was 1 complete response and 23 partial responses seen with T-DXd in this cohort, as well as 20 patients with stable disease. There was a disease control rate of 83%, made up by the stable disease plus the response rate.
In cohort B, with patients who had IHC 2+ and were ISH-negative; in cohort C, with patients who had IHC 1+, there were no responses observed. As expected, the therapy was active in patients with tumors that are HER2-positive and have IHC of 3+, or IHC of 2+ and ISH positive tumors, according to Siena.
